Change search
ReferencesLink to record
Permanent link

Direct link
Identification and management of poor response to growth-promoting therapy in children with short stature
Linköping University, Department of Clinical and Experimental Medicine. Linköping University, Faculty of Health Sciences.
University of Glasgow, Scotland .
Hospital Infantil University of Nino Jesus, Spain University of Autonoma Madrid, Spain Institute Salud Carlos III, Spain .
University of Cincinnati, USA .
Show others and affiliations
2012 (English)In: Clinical Endocrinology, ISSN 0300-0664, E-ISSN 1365-2265, Vol. 77, no 2, 169-181 p.Article, review/survey (Refereed) Published
Abstract [en]

Growth hormone (GH) is widely prescribed for children with short stature across a range of growth disorders. Recombinant human (rh) insulin-like growth factor-1 (rhIGF-1) therapy is approved for severe primary IGF-I deficiency a state of severe GH resistance. Evidence is increasing for an unacceptably high rate of poor or unsatisfactory response to growth-promoting therapy (i.e. not leading to significant catch up growth) in terms of change in height standard deviation score (SDS) and height velocity (HV) in many approved indications. Consequently, there is a need to define poor response and to prevent or correct it by optimizing treatment regimens within accepted guidelines. Recognition of a poor response is an indication for action by the treating physician, either to modify the therapy or to review the primary diagnosis leading either to discontinuation or change of therapy. This review discusses the optimal investigation of the child who is a candidate for GH or IGF-1 therapy so that a diagnosis-based choice of therapy and dosage can be made. The relevant parameters in the evaluation of growth response are described together with the definitions of poor response. Prevention of poor response is addressed by discussion of strategy for first-year management with GH and IGF-1. Adherence to therapy is reviewed as is the recommended action following the identification of the poorly responding patient. The awareness, recognition and management of poor response to growth-promoting therapy will lead to better patient care, greater cost-effectiveness and increased opportunities for clinical benefit.

Place, publisher, year, edition, pages
Blackwell Publishing / Society for Endocrinology , 2012. Vol. 77, no 2, 169-181 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-79650DOI: 10.1111/j.1365-2265.2012.04420.xISI: 000306223400002OAI: diva2:544313
Available from: 2012-08-14 Created: 2012-08-13 Last updated: 2012-09-27

Open Access in DiVA

fulltext(814 kB)653 downloads
File information
File name FULLTEXT01.pdfFile size 814 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full text

Search in DiVA

By author/editor
Bang, Peter
By organisation
Department of Clinical and Experimental MedicineFaculty of Health Sciences
In the same journal
Clinical Endocrinology
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
Total: 653 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 51 hits
ReferencesLink to record
Permanent link

Direct link